Steward Partners Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.4M | Buy |
20,851
+2,988
| +17% | +$1.32M | 0.05% | 338 |
|
|
2026
Q1 | $7.98M | Buy |
17,863
+499
| +3% | +$233K | 0.04% | 380 |
|
|
2025
Q4 | $7.87M | Sell |
17,364
-9,997
| -37% | -$4.31M | 0.04% | 357 |
|
|
2025
Q3 | $10.7M | Sell |
27,361
-14,190
| -34% | -$5.93M | 0.06% | 267 |
|
|
2025
Q2 | $18.5M | Buy |
41,551
+518
| +1% | +$239K | 0.14% | 144 |
|
|
2025
Q1 | $19.9M | Buy |
41,033
+1,225
| +3% | +$571K | 0.18% | 117 |
|
|
2024
Q4 | $16M | Sell |
39,808
-4,948
| -11% | -$2.29M | 0.14% | 141 |
|
|
2024
Q3 | $20.8M | Buy |
44,756
+4,075
| +10% | +$1.96M | 0.19% | 114 |
|
|
2024
Q2 | $19.1M | Sell |
40,681
-585
| -1% | -$254K | 0.2% | 100 |
|
|
2024
Q1 | $17.2M | Buy |
41,266
+6,299
| +18% | +$2.66M | 0.19% | 109 |
|
|
2023
Q4 | $14.2M | Buy |
34,967
+7,504
| +27% | +$2.77M | 0.19% | 115 |
|
|
2023
Q3 | $9.55M | Buy |
27,463
+6,619
| +32% | +$2.31M | 0.15% | 150 |
|
|
2023
Q2 | $7.34M | Buy |
20,844
+7,209
| +53% | +$2.43M | 0.11% | 196 |
|
|
2023
Q1 | $4.3M | Buy |
13,635
+1,938
| +17% | +$581K | 0.07% | 279 |
|
|
2022
Q4 | $3.38M | Buy |
11,697
+4,904
| +72% | +$1.49M | 0.06% | 327 |
|
|
2022
Q3 | $1.97M | Sell |
6,793
-102
| -1% | -$29.3K | 0.04% | 433 |
|
|
2022
Q2 | $1.94M | Sell |
6,895
-414
| -6% | -$111K | 0.04% | 441 |
|
|
2022
Q1 | $1.91M | Buy |
7,309
+3,898
| +114% | +$925K | 0.03% | 488 |
|
|
2021
Q4 | $749K | Sell |
3,411
-278
| -8% | -$54.1K | 0.01% | 796 |
|
|
2021
Q3 | $669K | Sell |
3,689
-671
| -15% | -$131K | 0.01% | 812 |
|
|
2021
Q2 | $879K | Sell |
4,360
-2,743
| -39% | -$574K | 0.01% | 726 |
|
|
2021
Q1 | $1.53M | Sell |
7,103
-3,109
| -30% | -$683K | 0.03% | 509 |
|
|
2020
Q4 | $2.41M | Buy |
10,212
+1,382
| +16% | +$317K | 0.05% | 333 |
|
|
2020
Q3 | $2.4M | Sell |
8,830
-546
| -6% | -$151K | 0.06% | 291 |
|
|
2020
Q2 | $2.72M | Buy |
9,376
+4,646
| +98% | +$1.26M | 0.08% | 245 |
|
|
2020
Q1 | $1.13M | Buy |
4,730
+354
| +8% | +$81.2K | 0.04% | 363 |
|
|
2019
Q4 | $958K | Buy |
4,376
+45
| +1% | +$9.11K | 0.03% | 467 |
|
|
2019
Q3 | $733K | Buy |
4,331
+1,124
| +35% | +$199K | 0.02% | 486 |
|
|
2019
Q2 | $588K | Buy |
3,207
+1,189
| +59% | +$208K | 0.02% | 515 |
|
|
2019
Q1 | $371K | Sell |
2,018
-31
| -2% | -$5.73K | 0.02% | 586 |
|
|
2018
Q4 | $339K | Buy |
2,049
+140
| +7% | +$24.3K | 0.02% | 577 |
|
|
2018
Q3 | $368K | Buy |
1,909
+13
| +0.7% | +$2.31K | 0.02% | 576 |
|
|
2018
Q2 | $322K | Sell |
1,896
-71
| -4% | -$11K | 0.02% | 548 |
|
|
2018
Q1 | $320K | Buy |
1,967
+234
| +14% | +$38.2K | 0.02% | 513 |
|
|
2017
Q4 | $259K | Buy |
1,733
+211
| +14% | +$31.2K | 0.02% | 475 |
|
|
2017
Q3 | $231K | Buy |
1,522
+201
| +15% | +$30.3K | 0.02% | 414 |
|
|
2017
Q2 | $170K | Buy |
1,321
+118
| +10% | +$14.2K | 0.02% | 428 |
|
|
2017
Q1 | $131K | Buy |
+1,203
| New | +$106K | 0.02% | 390 |
|
Other funds holding VRTX
Steward Partners Investment Advisory's VRTX Position: Q2 2026 in Review
Steward Partners Investment Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, buying an estimated $1.32M and bringing the position to 20,851 shares worth $10.4M. The position accounts for 0.05% of the portfolio, ranked #338.
Steward Partners Investment Advisory first reported a position in VRTX in Q1 2017 and has held it in 38 quarters since. The position peaked at $20.8M in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Steward Partners Investment Advisory held 20,851 shares of Vertex Pharmaceuticals worth $10.4M as of Q2 2026.
- Steward Partners Investment Advisory bought 2,988 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
- Vertex Pharmaceuticals made up 0.05% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #338 holding.
- Steward Partners Investment Advisory first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
- Steward Partners Investment Advisory's Vertex Pharmaceuticals position peaked at $20.8M in Q3 2024.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.